Meeting
2016 ASCO Annual Meeting
Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).
Authors
George D. Demetri
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
George D. Demetri , Margaret von Mehren , Robin Lewis Jones , Martee Leigh Hensley , Scott Schuetze , Anthony D. Elias , Renee F. Pierson , Roland Elmar Knoblauch , Youn C. Park , George C. Wang , Nushmia Z. Khokhar , Robert G Maki , Shreyaskumar Patel , Charles S. Cleeland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01343277
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11061)
DOI
10.1200/JCO.2016.34.15_suppl.11061
Abstract #
11061
Poster Bd #
187
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (Pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy.
First Author: Scott Schuetze
Poster
2023 ASCO Annual Meeting
The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.
First Author: Apar Kishor Ganti
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Symptom burden and functioning status in patients with advanced upper gastrointestinal cancers.
First Author: Xin Shelley Wang
Poster
2021 Gastrointestinal Cancers Symposium
Patient-reported symptom burden and functioning in patients with advanced esophageal, gastroesophageal junction (GEJ), and gastric cancer undergoing chemotherapy.
First Author: Xin Shelley Wang